This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 9, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reports preliminary data in the PREVAIL clinical trial met two out of three co-primary endpoints.
The PREVAIL trial evaluates safety and efficacy of the WATCHMAN® Left Atrial Appendage (LAA) Closure device in patients with nonvalvular atrial fibrillation versus long-term warfarin therapy. The device is designed to close off the LAA, a major source of clots in patients with atrial fibrillation, and reduce the risk of stroke, potentially eliminating the need for long-term use of blood-thinning medications.
The prospective, randomized PREVAIL trial enrolled 407 patients at 41 sites and compared the WATCHMAN device to warfarin in high-risk patients with nonvalvular atrial fibrillation eligible for long-term warfarin therapy. PREVAIL builds on data from the PROTECT AF clinical trial which enrolled 707 randomized patients treated with either the WATCHMAN device or standard warfarin therapy to evaluate the safety and effectiveness of the WATCHMAN technology. The PREVAIL trial was designed to confirm the results of the PROTECT AF trial and validate the safety of the implant procedure, including at least 25 percent of subjects treated by new operators.
Preliminary Results The PREVAIL trial met the pre-specified criteria for the first co-primary endpoint of occurrence of all-cause death, ischemic stroke, systemic embolism, or device or procedure-related events requiring open cardiac surgery or major endovascular intervention (randomization to seven days post procedure or by hospital discharge, whichever is later). The trial did not meet the pre-specified criteria for the second co-primary endpoint of the occurrence of all stroke (ischemic or hemorrhagic), cardiovascular death and systemic embolism at 18 months. While the second co-primary efficacy endpoint was not met, the device performed similar to warfarin with a rate ratio of 1.07. The PREVAIL trial met its pre-specified endpoint for the third co-primary endpoint of the composite of the occurrence of late ischemic stroke and systemic embolism (eight days post randomization and onward) at 18 months. The reported endpoint results are preliminary and require final validation.
Specifically, safety data demonstrated an increase in implant success rate overall (95.0 percent), and with new operators (93.2 percent), compared to PROTECT AF (90.9 percent). The overall seven-day serious procedure/device related complication rate was 4.4 percent in PREVAIL vs. 8.7 percent in PROTECT AF, a 49 percent relative reduction. A key result of the PREVAIL trial was that pericardial effusions requiring intervention occurred at a rate comparable to other left atrial procedures. PREVAIL reported a 1.9 percent event rate vs. 4.0 percent in PROTECT AF, a 52 percent relative reduction. Additionally, new operators had only one occurrence (1.0 percent) of pericardial effusion requiring intervention with no device embolization, peri-procedural strokes or cardiac perforation.